For research use only. Not for therapeutic Use.
Roflupram is a selective, orally active and brain-penetrant PDE4 inhibitor, with an IC50 of 26.2 nM for core catalytic domains of human PDE4. Roflupram can reverse cognitive deficits and reduce the production of pro-inflammatory factors[1][2].
| CAS Number | 1093412-18-0 |
| Synonyms | 1-[4-(difluoromethoxy)-3-(oxolan-3-yloxy)phenyl]-3-methylbutan-1-one |
| Molecular Formula | C16H20F2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H20F2O4/c1-10(2)7-13(19)11-3-4-14(22-16(17)18)15(8-11)21-12-5-6-20-9-12/h3-4,8,10,12,16H,5-7,9H2,1-2H3 |
| InChIKey | IXURVUHDDXFYDR-UHFFFAOYSA-N |
| SMILES | CC(C)CC(=O)C1=CC(=C(C=C1)OC(F)F)OC2CCOC2 |
| Reference | [1]. Li D, et, al. Roflupram, a novel phosphodiesterase 4 inhibitor, inhibits lipopolysaccharide-induced neuroinflammatory responses through activation of the AMPK/Sirt1 pathway. Int Immunopharmacol. 2021 Jan;90:107176. [2]. You T, et, al. Roflupram, a Phosphodiesterase 4 Inhibitior, Suppresses Inflammasome Activation through Autophagy in Microglial Cells. ACS Chem Neurosci. 2017 Nov 15;8(11):2381-2392. |
